Positive bird flu vaccine data drives Novavax shares; EMA supports Eli Lilly's Amyvid for Alzheimer's diagnosis;

Conversations on Twitter :

 @FierceBiotech: Wanted: Premier hepatitis C drug developer to partner with Vertex. More | Follow @FierceBiotech

 @JohnCFierce: $1.2B in VC for biotech in Q3 not the best ever, but a whole lot more than we've been seeing--so I see it as a solid +. More | Follow @JohnCFierce

> Shares of Novavax ($NVAX) got a boost out of the news that two early-stage studies of its bird flu vaccine produced positive results. Story

> The EMA is recommending approval of Eli Lilly's ($LLY) Amyvid, a radioactive dye that can be used to help clinicians diagnose Alzheimer's. Story

> Chapel Hill, NC-based Cempra says it raised $25 million from the sale of shares. The biotech will earmark much of that to fund clinical trials. Release

> Histogen is touting early-stage evidence of efficacy for its "Hair Stimulating Complex." Release

Pharma News

@FiercePharma: More drug payment/pricing action in Greece. Some brand meds said to be struck from formulary. Article | Follow @FiercePharma

> Actavis CEO: Biosims market will be tough to crack. Report

> GSK CEO remains 'a huge bull on India.' Story

> EMA committee shoots down Vivus diet pill. Article

Medical Device News

 @FierceMedDev: VC investment in Q3 is way down for medical devices. More | Follow @FierceMedDev

 @MarkHFierce: So what were the top med device VC deals in the 2012 third quarter? More | Follow @MarkHFierce

 @DamianFierce: Steris is spending $110M on M&A to expand its surgical device capabilities. More | Follow @DamianFierce

> Complete Genomics scores patent win over Illumina. Story

> Study: To reduce heart disease risks, gastric banding beats drugs. News

> Sony slashes jobs on road to medical device focus. Item

And Finally… In a new study published in Nature, scientists point to mutations in neural stem cells as a likely new suspect involved in the hunt to determine what triggers Parkinson's disease. Story


Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.